Status: Recruiting

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.

Participants needed: 60

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 8, 2026Locations: 1

Eligibility criteria

Age ≥18 years. [+42]

Prior treatment with PRMT5 and MAT2A inhibitors. [+31]

Status: Recruiting

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.

Participants needed: 30

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 20, 2026Locations: 1

Eligibility criteria

Confirmed diagnosis of mantle cell lymphoma by hematopathology. MCL should have... [+3]

Isolated bone marrow or GI only disease MCL participants and/or lack of any meas... [+43]

Status: Not yet recruiting

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.

Participants needed: 40

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 5, 2026Locations: 1

Eligibility criteria

Participants of age ≥18 years with documented B-cell ALL with recurrent or persi... [+9]

Pregnant women are excluded from this study because Blinatumomab, a bispecific T... [+14]